Expired Research Opportunities
Preclinical Development
Initiatives to conduct product refinement testing. This page includes EXPIRED funding opportunities only.
Focus: To support the development of new vaccines, vaccine technologies, adjuvants, therapeutics, immunotherapeutics or medical diagnostics focused on NIAID Category A, B, or C priority pathogens and toxins
Contact Info
Dr. Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Focus: To fund organizations with demonstrated vaccine product development experience to produce a vaccine candidate either for a NIAID Category A or B Priority Pathogen (PART A) or a candidate third generation anthrax vaccine (PART B).
Contact Info
Jordan Pulaski
Email: jpulaski@niaid.nih.gov
Focus: To support the development of a prophylactic multivalent filovirus vaccine that is capable of protecting against both Ebola and Marburg viruses, utilizing platform technology such that the same basic development and manufacturing process is used to develop each component of the final multivalent vaccine.
Contact Info
Heidi Holley
Email: holleyh@niaid.nih.gov
Focus: To support projects to advance the development of promising candidate therapeutics with demonstrated in vivo activity against NIAID biodefense priority pathogens.
Contact Info
Suzanne Dawkins
E-mail: DLisle@niaid.nih.gov
Relevent Dates
Focus: To support discovery/design and development of vaccines, therapeutics, immunotherapeutics, adjuvants, and medical diagnostics for NIAID Category A, B, and C priority pathogens and toxins
Contact Info
Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Focus: To support cooperative translational research into developing therapeutics and diagnostics for certain biodefense toxins: Shiga toxins, ricin toxin, the Staphylococcus enterotoxin B (SEB), Clostridium perfringens epsilon toxin, and the botulinum neurotoxins.
Contact Info
General scientific, technical, and programmatic issues: Clare K. Schmitt
E-mail: CSchmitt@niaid.nih.gov
Therapeutics and immunotherapeutics questions: Lillian Van De Verg
E-mail: LVanDeVerg@niaid.nih.gov
Diagnostics questions: Robert H. Hall
E-mail: rhall@niaid.nih.gov
Focus: To support translational research and pre-clinical product development of new therapeutics and diagnostics addressing NIAID Category B priority pathogens.
Contact Info
General scientific and programmatic issues and questions, Category B bacteria: Robert Hall
E-mail: rhall@niaid.nih.gov
Questions related to Category B viruses: Cristina Cassetti
E-mail: ccassetti@niaid.nih.gov
Questions related to Category B Parasites: Philip Coyne
E-mail: pcoyne@niaid.nih.gov
Focus: To support the development and testing of an anthrax vaccine candidate that improves upon the second-generation anthrax vaccines by possessing the following characteristics: (1) should be suitable for storage in the Strategic National Stockpile, (2) should elicit a rapid immune response, (3) and should utilize a platform that shall allow non-technical persons to perform inoculations or self-administration.
Contact Info
Ross Kelley
E-mail: rkelley@niaid.nih.gov
Focus: To support research that will advance the development of vaccines, adjuvants, therapeutics, immunotherapeutics, and diagnostics for influenza technologies through the product development pathway.
Contact Info
General scientific, technical, and programmatic issues; vaccines, therapeutics, and immunotherapeutics: David Cho
E-mail: choda@niaid.nih.gov
Cooperative research partnerships: Michael Schaefer
E-mail: mschaefer@niaid.nih.gov
Adjuvants: Sonnie Kim
E-mail: skim@niaid.nih.gov
Diagnostics: Karen Lacourciere
E-mail: lacourcierek@niaid.nih.gov
Focus: To advance the development of candidate therapeutics with (1) demonstrated activity against one or more of the selected NIAID Category A and B biothreat bacterial pathogens or (2) broad spectrum activity against any of the Category C antimicrobial resistant pathogens and one more of the selected Category A and B bacterial pathogens. Product development shall be via a focused, staged approach and include candidate therapeutics within the regulatory purview of the Center for Drug Evaluation and Review (CDER) of the U.S. Food and Drug Administration (FDA).
Contact Info
Carl Newman
E-mail: cnewman@niaid.nih.gov
Focus: To develop new, safe, and effective therapeutics for Variola major and viral hemorrhagic fevers, viral encephalitides, and influenza.
Contact Info
Liem Nguyen
E-mail: ln18x@nih.gov
Focus: To establish a resource to facilitate preclinical development of therapeutic agents (drugs or biological products), including activities required for Investigational New Drug applications.
Contact Info
Erin Goldstein
E-mail: EGoldstein@niaid.nih.gov
back to top